Provista Diagnostics Announces Results of Annual Shareholder Meeting

company logo

Scottsdale, AZ, May 6, 2013 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a leading molecular diagnostics company focused on developing and commercializing proprietary diagnostic, prognostic and predictive tests for cancers affecting women, today announced the results of its 2013 Annual Meeting of Stockholders held on May 2, 2013 in New York City.

Provista is pleased to announce that by an overwhelming majority, the shareholders of the Company's preferred and common stock re-elected all of the Director nominees listed in its information circular dated April 19, 2013 as directors of the Company to serve until the 2014 Annual Meeting of Stockholders. Members of the Company's Board of Directors are Anne Busquet, Jeffrey R. Gilman, Robert J. Hariri M.D., Ph.D., Jack Levine CFA, John Macaskill, David E. Reese, Ph.D. and John Zicarelli Ph.D., FCAS, CFA.

About Provista

Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing through its dtectDx platform, proprietary diagnostic, prognostic and predictive tests for cancers affecting women, including breast, endometrial and ovarian. Provista also offers diagnostic testing and clinical laboratory services to the pharmaceutical and biotechnology industries through its PDx Reference Laboratory, a CLIA-accredited and GLP capable laboratory, licensed in 49 states to perform human clinical testing. More information about Provista is available at

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT: John N. Fermanis +1 602 224 5500

Source:Provista Diagnostics, Inc.